US drugmaker Pfizer has brought its Rimegepant (Orally Disintegrating Tablet -ODT) to India, to treat acute migraine, in adults with a previous insufficient response to triptan.

“The new medication delivers rapid and sustained pain relief lasting up to 48 hours post-treatment,,” the company said, adding that Rimegepant would be available in a 75 mg ODT form, designed for convenient administration without water.

“Rimegepant sets a new standard in comprehensive migraine care in the Indian market by providing timely and quick pain relief for migraine patients. By targeting one of the key elements of migraine’s pathophysiology – calcitonin gene-related peptide (CGRP) – this medication offers prompt and effective relief,” the company said.

Meenakshi Nevatia, Managing Director, Pfizer Ltd sai

See Full Page